PTPRC and neoplasm: In confirmatory flow experiments, we observed a significant increase in CD45+ cells and a significant decrease in tumor cells (28% vs 5%, p = 0.0045) relative to total live cells in treatment group within the metastatic liver tumor (Fig. 6e).